drugset / Trial / NCT06717113

A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

NCT06717113

Phase 0 Recruiting 50 enrolled Peking University First Hospital
Non-randomizedCrossoverOpen-labelDiagnostic

Summary

Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.

Timeline

Start
2025-04-15
Primary completion
2025-12-31
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator 18F-FDG Diagnostic / imaging agent 1.85 mbq/kg Intravenous
Comparator 18F-FDG Diagnostic / imaging agent 3.7 mbq/kg Intravenous
Subject 68Ga-BC1 Unknown 1.85 mbq/kg Intravenous
Subject 68Ga-BC1 Unknown 3.7 mbq/kg Intravenous

Indications